PolyPid Ltd.
NASDAQ:PYPDBiotechnology
+$0.39 today
- Market cap
- $133.25M
- Beta
- 1.43
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$1.53
Volume 0.30M
Average 0.09M
PYPD Income Tax Expense
Income taxes recognized for the period, including current and deferred tax.
PolyPid Ltd.NASDAQ: PYPD
Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026
Income tax expense remains negative
Q1 FY2026 income tax expense was $0, compared with $11K a year earlier. Trailing-twelve-month income tax expense was -$6K. Over 3 fiscal years it compounded at -66.2% a year.
Context
- Income tax expense increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$1.5K.
Sources:Income StatementText generated from reported figures; not investment advice.
Income Tax Expense history
USD · from the income statement
- Latest · FY2025
- 5K USD
- Year-over-year change
- -88.1%
| Period | Period end | Income Tax Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5K | -88.1% |
| FY2024 | 2024-12-31 | 42K | -39.1% |
| FY2023 | 2023-12-31 | 69K | -46.5% |
| FY2022 | 2022-12-31 | 129K | — |
| FY2021 | 2021-12-31 | 0 | — |
Income Tax Expense vs competitors
How PYPD compares with its peers on the latest reported figures
- PYPD's LTM Mar 2026 income tax expense of -$6K is the lowest of the 7 companies compared; the peer median is $0.
- Its year-over-year change of -113.0% is the lowest of 3, against a peer median of +0.0%.
- Over three fiscal years its annual growth of -66.2% compares with a peer median of -38.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | +100.0% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| LTM Dec 2025 | $0 | — | -38.7% | 0.0% | |
| LTM Mar 2026 | -$6K | -113.0% | -66.2% | — | |
| Peer median (excluding PYPD) | $0 | +0.0% | -38.7% | 0.0% | |
Competitors are the stored peer set for PYPD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 1.12M | 1.72M | 0 | 0 | 0 |
| Gross Profit | (1.12M) | (1.72M) | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 30.42M | 27.99M | 16.15M | 22.81M | 23.81M |
| Selling, General & Admin | 12.45M | 10.9M | 6.72M | 5.22M | 9.16M |
| Operating Expenses | 42.03M | 37.17M | 22.87M | 28.03M | 32.97M |
| Depreciation & Amortization | 1.12M | 1.72M | 1.82M | 1.62M | 1.62M |
| EBITDA | (41.48M) | (36.37M) | (20.26M) | (25.83M) | (31.86M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (43.15M) | (38.89M) | (22.87M) | (28.03M) | (32.97M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 468K | 267K | 548K | 442K | 0 |
| Interest Expense | 0 | 1.34M | 1.71M | 1.53M | 685K |
| Other Income / Expenses | 544K | (540K) | (929K) | (951K) | (1.2M) |
| Income Before Tax | (42.6M) | (39.43M) | (23.8M) | (28.98M) | (34.16M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 129K | 69K | 42K | 5K |
| Net Income | (40.71M) | (39.53M) | (23.87M) | (29.02M) | (34.17M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (67.80) | (61.20) | (16.99) | (4.91) | (2.09) |
| EPS (Diluted) | (67.80) | (61.20) | (16.99) | (4.91) | (2.09) |
| Weighted Avg Shares | 1.25M | 1.3M | 1.4M | 5.91M | 16.35M |
| Weighted Avg Shares (Diluted) | 1.25M | 1.3M | 1.4M | 5.91M | 16.35M |
PolyPid Ltd.
NASDAQ:PYPD
Intrinsic Alpha fair value
Locked
Current Price
$6.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.